Pharvaris to Present Data at Upcoming Congresses

Pharvaris, a biopharmaceutical company based in Zug, Switzerland, has announced the acceptance of several abstracts for presentation at three significant upcoming scientific gatherings. These include the 20th Annual Congress of International Drug Discovery Science and Technology (IDDST) in Osaka, Japan; the 2024 Eastern Allergy Conference (EAC) in Palm Beach, Florida; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 in Valencia, Spain. The focus of these presentations will be on Deucrictibant, Pharvaris' novel oral bradykinin B2 receptor antagonist, which is being developed to treat and prevent hereditary angioedema (HAE) attacks.

At the IDDST 2024, taking place from May 22 to 24 in Osaka, the presentation titled "Pharmacological Profile of Deucrictibant, a Small-molecule Bradykinin B2 Receptor Antagonist in Clinical Development for Hereditary Angioedema" will be delivered by Dr. Anne Lesage. This oral presentation is scheduled for May 22 from 10:55 to 11:20 a.m. JST.

The EAC 2024 in Palm Beach, Florida, scheduled from May 30 to June 2, will feature a poster presentation by Dr. Henry Li on June 1 from 9:45 to 11:00 a.m. EDT. The presentation is titled "Relief and Resolution of Attack Symptoms Following On-Demand Treatment With a Single Dose of Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients With Hereditary Angioedema."

At the EAACI Congress 2024 in Valencia, Spain, from May 31 to June 3, Pharvaris will present multiple abstracts. On June 1 at 17:21 CEST, Dr. Emel Aygören-Pürsün will present "Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial." Immediately following, at 17:33 CEST, Dr. Anna Valerieva will discuss "Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema."

On June 2, multiple poster presentations will occur simultaneously at 13:15 CEST. Dr. Marcus Maurer will discuss the "Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design." Dr. Laurence Bouillet will explore "Exploring the Relationship Between Airway Attacks and Patient-Reported Outcomes in Hereditary Angioedema Attacks." Dr. Anne Lesage will present "Pharmacodynamic Effects of Deucrictibant on Carrageenan-induced Edema in Humanized Bradykinin B2 Receptor Transgenic Sprague Dawley Rat." Finally, Dr. Evangelia Pardali will present "Development of Kallikrein-Kinin System Biomarker Assays to Investigate Bradykinin-mediated Diseases."

The abstracts presented at the EAACI Congress will be published in the European Journal of Allergy and Clinical Immunology, "Allergy," following the event. Additionally, the posters and presentation slides will be accessible on the Pharvaris website in the Investors section at the start of each presentation session.

Pharvaris continues to leverage its profound expertise in hereditary angioedema (HAE) to develop novel, oral therapeutic options for managing the condition. The company's commitment is to provide effective, safe, and convenient treatment alternatives for individuals with all forms of HAE.